nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Sirolimus—FGF2—cleft lip	0.036	1	CrCbGaD
Everolimus—MTOR—PI-3K cascade—FGFR1—cleft lip	0.00232	0.0024	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGF10—cleft lip	0.00232	0.0024	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGF3—cleft lip	0.00231	0.00239	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—FGFR3—cleft lip	0.0023	0.00239	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—FGFR3—cleft lip	0.0023	0.00239	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGF3—cleft lip	0.0023	0.00238	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF9—cleft lip	0.00229	0.00237	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGF9—cleft lip	0.00229	0.00237	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGF9—cleft lip	0.00229	0.00237	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGF9—cleft lip	0.00227	0.00235	CbGpPWpGaD
Everolimus—MTOR—PI3K Cascade—FGF2—cleft lip	0.00227	0.00235	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FGFR1—cleft lip	0.00226	0.00235	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGF9—cleft lip	0.00225	0.00233	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FGFR1—cleft lip	0.00224	0.00233	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGF9—cleft lip	0.00224	0.00232	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGF10—cleft lip	0.00222	0.0023	CbGpPWpGaD
Everolimus—FKBP1A—Disease—WNT9B—cleft lip	0.00221	0.00229	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR1—cleft lip	0.00219	0.00227	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—FGFR3—cleft lip	0.00219	0.00227	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGF10—cleft lip	0.00218	0.00226	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGF3—cleft lip	0.00217	0.00225	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGFR2—cleft lip	0.00217	0.00225	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—MYC—cleft lip	0.00214	0.00222	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FGFR3—cleft lip	0.00214	0.00222	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGF7—cleft lip	0.00213	0.00221	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FGFR3—cleft lip	0.00212	0.0022	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGF9—cleft lip	0.00212	0.0022	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGF10—cleft lip	0.00208	0.00216	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF3—cleft lip	0.00208	0.00216	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—cleft lip	0.00207	0.00215	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGF10—cleft lip	0.00207	0.00215	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—NOS3—cleft lip	0.00207	0.00214	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGF10—cleft lip	0.00206	0.00214	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGF10—cleft lip	0.00205	0.00213	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF9—cleft lip	0.00203	0.0021	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGFR1—cleft lip	0.00202	0.0021	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGF10—cleft lip	0.00202	0.0021	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—MYC—cleft lip	0.00199	0.00207	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ABCA4—cleft lip	0.00197	0.00204	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGF8—cleft lip	0.00196	0.00204	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGF10—cleft lip	0.00193	0.002	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF10—cleft lip	0.00193	0.002	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGF10—cleft lip	0.00193	0.002	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—FGF2—cleft lip	0.00191	0.00199	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGFR3—cleft lip	0.00191	0.00199	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGF10—cleft lip	0.00191	0.00198	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—FGF2—cleft lip	0.0019	0.00197	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGF10—cleft lip	0.0019	0.00197	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGF10—cleft lip	0.00189	0.00196	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGF2—cleft lip	0.00188	0.00195	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGFR2—cleft lip	0.00186	0.00193	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—FGF2—cleft lip	0.00184	0.00191	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—MYC—cleft lip	0.00184	0.00191	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—FGF2—cleft lip	0.00183	0.0019	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC19A1—cleft lip	0.0018	0.00187	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGF10—cleft lip	0.00179	0.00185	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—MYC—cleft lip	0.00178	0.00185	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—FGF2—cleft lip	0.00178	0.00185	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—FGF2—cleft lip	0.00178	0.00185	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGFR2—cleft lip	0.00178	0.00184	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.00176	0.00183	CbGpPWpGaD
Everolimus—FKBP1A—Disease—WNT3—cleft lip	0.00176	0.00182	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGFR2—cleft lip	0.00175	0.00182	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGFR1—cleft lip	0.00173	0.0018	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF10—cleft lip	0.00171	0.00177	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—MYC—cleft lip	0.0017	0.00176	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—FGF2—cleft lip	0.00169	0.00176	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGFR2—cleft lip	0.00167	0.00173	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGFR2—cleft lip	0.00166	0.00173	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGFR1—cleft lip	0.00166	0.00172	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGFR2—cleft lip	0.00165	0.00172	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FGF2—cleft lip	0.00165	0.00171	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGFR2—cleft lip	0.00165	0.00171	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FGF2—cleft lip	0.00164	0.0017	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGFR3—cleft lip	0.00164	0.0017	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGFR1—cleft lip	0.00163	0.00169	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR2—cleft lip	0.00162	0.00168	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGF2—cleft lip	0.0016	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGF3—cleft lip	0.0016	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ARHGAP29—cleft lip	0.00159	0.00165	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—cleft lip	0.00157	0.00162	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGF9—cleft lip	0.00156	0.00162	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGFR1—cleft lip	0.00156	0.00162	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—cleft lip	0.00156	0.00161	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGFR1—cleft lip	0.00155	0.00161	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGFR2—cleft lip	0.00155	0.00161	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR2—cleft lip	0.00155	0.00161	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGFR2—cleft lip	0.00155	0.00161	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—WNT9B—cleft lip	0.00155	0.00161	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGFR1—cleft lip	0.00154	0.0016	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGFR3—cleft lip	0.00154	0.0016	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGFR2—cleft lip	0.00154	0.00159	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGFR1—cleft lip	0.00153	0.00159	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGFR2—cleft lip	0.00152	0.00158	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—MYC—cleft lip	0.00152	0.00157	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGFR2—cleft lip	0.00152	0.00157	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR1—cleft lip	0.00151	0.00157	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TCN2—cleft lip	0.00149	0.00155	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOG—cleft lip	0.00148	0.00154	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—MYC—cleft lip	0.00148	0.00154	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGF2—cleft lip	0.00148	0.00153	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGFR3—cleft lip	0.00147	0.00153	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NOS3—cleft lip	0.00147	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGFR3—cleft lip	0.00146	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGFR3—cleft lip	0.00146	0.00151	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGFR3—cleft lip	0.00145	0.0015	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGFR1—cleft lip	0.00144	0.0015	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR1—cleft lip	0.00144	0.0015	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGFR1—cleft lip	0.00144	0.0015	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGFR2—cleft lip	0.00143	0.00149	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGFR1—cleft lip	0.00143	0.00148	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—cleft lip	0.00143	0.00148	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGFR1—cleft lip	0.00142	0.00147	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGFR1—cleft lip	0.00141	0.00146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ABCA4—cleft lip	0.00138	0.00143	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR2—cleft lip	0.00137	0.00142	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGFR3—cleft lip	0.00136	0.00142	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGFR3—cleft lip	0.00136	0.00142	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—cleft lip	0.00136	0.00142	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGFR3—cleft lip	0.00135	0.0014	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—cleft lip	0.00134	0.00139	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGFR1—cleft lip	0.00134	0.00139	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGFR3—cleft lip	0.00133	0.00138	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGF10—cleft lip	0.00132	0.00136	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR1—cleft lip	0.00128	0.00133	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGF2—cleft lip	0.00127	0.00131	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGFR3—cleft lip	0.00126	0.00131	CbGpPWpGaD
Everolimus—MTOR—Disease—WNT9B—cleft lip	0.00124	0.00129	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—WNT3—cleft lip	0.00123	0.00128	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF7—cleft lip	0.00121	0.00126	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGF2—cleft lip	0.00121	0.00126	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—cleft lip	0.00121	0.00125	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGF2—cleft lip	0.00119	0.00124	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF7—cleft lip	0.00117	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF7—cleft lip	0.00116	0.0012	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SPRY2—cleft lip	0.00116	0.0012	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.00115	0.0012	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGF2—cleft lip	0.00114	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGF2—cleft lip	0.00113	0.00117	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRF6—cleft lip	0.00113	0.00117	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGF2—cleft lip	0.00113	0.00117	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGF2—cleft lip	0.00112	0.00116	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF8—cleft lip	0.00112	0.00116	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—cleft lip	0.00112	0.00116	CbGpPWpGaD
Everolimus—MTOR—Disease—ABCA4—cleft lip	0.00111	0.00115	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGF2—cleft lip	0.0011	0.00115	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF8—cleft lip	0.00108	0.00112	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF8—cleft lip	0.00107	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGFR2—cleft lip	0.00106	0.00109	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGF2—cleft lip	0.00105	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGF2—cleft lip	0.00105	0.00109	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF2—cleft lip	0.00105	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGF2—cleft lip	0.00105	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGF2—cleft lip	0.00104	0.00107	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTR—cleft lip	0.00103	0.00107	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGF2—cleft lip	0.00103	0.00107	CbGpPWpGaD
Everolimus—MTOR—Disease—SLC19A1—cleft lip	0.00101	0.00105	CbGpPWpGaD
Everolimus—MTOR—Disease—WNT3—cleft lip	0.000987	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGFR1—cleft lip	0.000984	0.00102	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGF2—cleft lip	0.000976	0.00101	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF2—cleft lip	0.000934	0.000969	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGFR3—cleft lip	0.00093	0.000964	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF3—cleft lip	0.000912	0.000946	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF9—cleft lip	0.000889	0.000923	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF3—cleft lip	0.000876	0.000909	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF3—cleft lip	0.000872	0.000905	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—WNT9B—cleft lip	0.00087	0.000903	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF9—cleft lip	0.000854	0.000886	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF9—cleft lip	0.00085	0.000882	CbGpPWpGaD
Everolimus—MTOR—Disease—TCN2—cleft lip	0.00084	0.000871	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOG—cleft lip	0.000834	0.000866	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SPRY2—cleft lip	0.000813	0.000843	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF7—cleft lip	0.000813	0.000843	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—cleft lip	0.000783	0.000812	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ABCA4—cleft lip	0.000776	0.000805	CbGpPWpGaD
Everolimus—MTOR—Immune System—SUMO1—cleft lip	0.000773	0.000802	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—MTR—cleft lip	0.000756	0.000784	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF8—cleft lip	0.00075	0.000778	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF10—cleft lip	0.00075	0.000778	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF10—cleft lip	0.00072	0.000747	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGF2—cleft lip	0.000718	0.000745	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF10—cleft lip	0.000717	0.000744	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF7—cleft lip	0.000707	0.000734	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—WNT3—cleft lip	0.000691	0.000717	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTCH1—cleft lip	0.000674	0.000699	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF7—cleft lip	0.000653	0.000677	CbGpPWpGaD
Everolimus—MTOR—Disease—SPRY2—cleft lip	0.000653	0.000677	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF8—cleft lip	0.000653	0.000677	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF3—cleft lip	0.000611	0.000634	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF8—cleft lip	0.000603	0.000625	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGFR2—cleft lip	0.000602	0.000624	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF9—cleft lip	0.000595	0.000618	CbGpPWpGaD
Everolimus—MTOR—Disease—MTR—cleft lip	0.000582	0.000604	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR2—cleft lip	0.000578	0.0006	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR2—cleft lip	0.000576	0.000597	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGFR1—cleft lip	0.000561	0.000582	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—cleft lip	0.000554	0.000575	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR1—cleft lip	0.000539	0.000559	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR1—cleft lip	0.000536	0.000557	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF3—cleft lip	0.000531	0.000551	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGFR3—cleft lip	0.00053	0.00055	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF9—cleft lip	0.000518	0.000537	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR3—cleft lip	0.000509	0.000528	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR3—cleft lip	0.000507	0.000526	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF10—cleft lip	0.000502	0.000521	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF3—cleft lip	0.00049	0.000509	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF9—cleft lip	0.000478	0.000496	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPRY2—cleft lip	0.000457	0.000474	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF7—cleft lip	0.000457	0.000474	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF10—cleft lip	0.000437	0.000453	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF8—cleft lip	0.000422	0.000438	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF2—cleft lip	0.00041	0.000425	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF10—cleft lip	0.000403	0.000418	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR2—cleft lip	0.000403	0.000418	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF2—cleft lip	0.000394	0.000408	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF2—cleft lip	0.000392	0.000406	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—cleft lip	0.000386	0.000401	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTCH1—cleft lip	0.000379	0.000393	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR1—cleft lip	0.000376	0.00039	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR3—cleft lip	0.000355	0.000368	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR2—cleft lip	0.000351	0.000364	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF3—cleft lip	0.000343	0.000356	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF9—cleft lip	0.000335	0.000347	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR1—cleft lip	0.000327	0.000339	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR2—cleft lip	0.000324	0.000336	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—cleft lip	0.000312	0.000323	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR3—cleft lip	0.000309	0.00032	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR1—cleft lip	0.000302	0.000313	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR3—cleft lip	0.000285	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF10—cleft lip	0.000282	0.000293	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF2—cleft lip	0.000274	0.000285	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—cleft lip	0.000271	0.000281	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—cleft lip	0.000256	0.000266	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF2—cleft lip	0.000239	0.000248	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR2—cleft lip	0.000227	0.000235	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC19A1—cleft lip	0.000225	0.000233	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF2—cleft lip	0.00022	0.000229	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—cleft lip	0.000217	0.000225	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR1—cleft lip	0.000211	0.000219	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR3—cleft lip	0.0002	0.000207	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TCN2—cleft lip	0.000186	0.000193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—cleft lip	0.000179	0.000186	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF2—cleft lip	0.000154	0.00016	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—cleft lip	0.000152	0.000158	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—cleft lip	0.000144	0.000149	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTR—cleft lip	0.000129	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—cleft lip	0.000101	0.000105	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—cleft lip	7.92e-05	8.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—cleft lip	6.92e-05	7.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—cleft lip	4.83e-05	5.01e-05	CbGpPWpGaD
